https://www.zerohedge.com/markets/central-banks-turn-gold-losses-mount BTC is the best performing asset this year... Juss sayin :DD
Zerohedge
Zerohedge
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
https://www.rt.com/business/570412-el-salvador-pays-sovereign-debt/ Imagine the look on the IMF and central banksters pinched faces when they hear the news :D Oh, thats made my day !!!!
RT
Crypto-friendly El Salvador pays its sovereign debt dues
El Salvador has paid in full an $800 million bond maturing this month, President Nayib Bukele has announced
🔥1
Forwarded from Bitcoin
Despite a smear campaign, El Salvador was successfully able to pay off an $800 million bond!
President Nayib Bukele sheds light on mainstream tactics to discredit the country and Bitcoin.
https://www.btctimes.com/news/el-salvador-paid-off-bond-maturing-in-2023-despite-media-doubts
President Nayib Bukele sheds light on mainstream tactics to discredit the country and Bitcoin.
https://www.btctimes.com/news/el-salvador-paid-off-bond-maturing-in-2023-despite-media-doubts
BTC Times
El Salvador Paid off Bond Maturing in 2023 Despite Media Doubts
On January 24th, 2023 El Salvador’s president, Nayib Bukele, announced that the country was able to pay off an $800 million bond despite numerous media outlets claiming that it would not be able to make payments because of its “Bitcoin bet.”
The payment…
The payment…
👍1🔥1
jiac317.pdf
833.4 KB
Oxford Journal of Infectious Diseases (January 2023 issue Drop 1 of 3)
In this first issue of the OJID for 2023, we have some very interesting studies to go over.
It looks like the mRNA shots, being reverse transcribed into your DNA, is finally beginning to be taken seriously by mainstream academia. There's also some interesting studies on the rise in RSV cases during the last 3 years and something I covered in my series on the Pfizer FOIA documents releases.
1) Sensitivity of Reverse Trannoscription Polymerase Chain Reaction Tests for SARSCov 2 Through Time
2) Memory B-Cell Development After Asymptomatic or Mild Symptomatic SARS-CoV-2 Infection
3) Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
4) Potent Neutralizing Activity of Polyclonal Equine Antibodies Against SARS Cov 2 Variants of Concern
5) SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody- Mediated Immunity
In this first issue of the OJID for 2023, we have some very interesting studies to go over.
It looks like the mRNA shots, being reverse transcribed into your DNA, is finally beginning to be taken seriously by mainstream academia. There's also some interesting studies on the rise in RSV cases during the last 3 years and something I covered in my series on the Pfizer FOIA documents releases.
1) Sensitivity of Reverse Trannoscription Polymerase Chain Reaction Tests for SARSCov 2 Through Time
2) Memory B-Cell Development After Asymptomatic or Mild Symptomatic SARS-CoV-2 Infection
3) Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
4) Potent Neutralizing Activity of Polyclonal Equine Antibodies Against SARS Cov 2 Variants of Concern
5) SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody- Mediated Immunity
🔥1
jiac382.pdf
1.2 MB
Oxford Journal of Infectious Diseases (January 2023 issue Drop 2 of 3)
1) An RSV Live-Attenuated Vaccine Candidate Lacking G Protein Mucin Domains Is Attenuated, Immunogenic, and Effective in Preventing RSV in BALB/c Mice
2) Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
3) Perturbations in Respiratory Syncytial Virus Activity During the SARS-CoV-2 Pandemic
4) Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
5) Differences in New Variant of Concern Replication at Physiological Temperatures In Vitro
6) Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
7) Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant
1) An RSV Live-Attenuated Vaccine Candidate Lacking G Protein Mucin Domains Is Attenuated, Immunogenic, and Effective in Preventing RSV in BALB/c Mice
2) Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
3) Perturbations in Respiratory Syncytial Virus Activity During the SARS-CoV-2 Pandemic
4) Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
5) Differences in New Variant of Concern Replication at Physiological Temperatures In Vitro
6) Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
7) Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant